Nanobiotix S.A. (0QAV.L)

EUR 3.05

(1.5%)

Net Debt Summary of Nanobiotix S.A.

Nanobiotix S.A.'s latest annual net debt in 2023 was -29.8 Million EUR , down -269.39% from previous year.
Nanobiotix S.A.'s latest quarterly net debt in 2024 Q2 was -21.85 Million EUR , down 0.0% from previous quarter.
Nanobiotix S.A. reported annual net debt of 14.59 Million EUR in 2022, up 138.5% from previous year.
Nanobiotix S.A. reported annual net debt of -37.9 Million EUR in 2021, up 45.99% from previous year.
Nanobiotix S.A. reported quarterly net debt of -24.71 Million EUR for 2023 FY, down -269.39% from previous quarter.
Nanobiotix S.A. reported quarterly net debt of -25.91 Million EUR for 2023 Q4, down 0.0% from previous quarter.

Annual Net Debt Chart of Nanobiotix S.A. (2023 - 2012)

Historical Annual Net Debt of Nanobiotix S.A. (2023 - 2012)

Year	Net Debt	Net Debt Growth
2023	-29.8 Million EUR	-269.39%
2022	14.59 Million EUR	138.5%
2021	-37.9 Million EUR	45.99%
2020	-70.17 Million EUR	-843.98%
2019	9.43 Million EUR	160.15%
2018	-15.68 Million EUR	63.09%
2017	-42.48 Million EUR	-176.03%
2016	-15.39 Million EUR	-24.1%
2015	-12.4 Million EUR	59.55%
2014	-30.66 Million EUR	-687.18%
2013	-3.89 Million EUR	68.49%
2012	-12.36 Million EUR	0.0%

Year	Net Debt	Net Debt Growth
2024 Q2	-21.85 Million EUR	0.0%
2023 FY	-24.71 Million EUR	-269.39%
2023 Q4	-25.91 Million EUR	0.0%
2023 Q2	32.37 Million EUR	0.0%
2022 Q4	14.59 Million EUR	0.0%
2022 Q2	-17.91 Million EUR	0.0%
2022 FY	14.59 Million EUR	138.5%
2021 FY	-37.9 Million EUR	45.99%
2021 Q4	-37.9 Million EUR	0.0%
2021 Q2	-51.61 Million EUR	0.0%
2020 Q2	25.24 Million EUR	0.0%
2020 FY	-70.17 Million EUR	-843.98%
2020 Q4	-70.17 Million EUR	0.0%
2019 Q4	9.43 Million EUR	0.0%
2019 FY	9.43 Million EUR	160.15%
2019 Q2	-7.03 Million EUR	0.0%
2018 FY	-15.68 Million EUR	63.09%
2018 Q4	-15.68 Million EUR	0.0%
2018 Q2	-28.66 Million EUR	0.0%
2017 FY	-42.48 Million EUR	-176.03%
2017 Q4	-42.69 Million EUR	0.0%
2017 Q2	-25.98 Million EUR	0.0%
2016 Q2	-20.44 Million EUR	0.0%
2016 FY	-15.39 Million EUR	-24.1%
2016 Q4	-15.39 Million EUR	0.0%
2015 Q4	-12.4 Million EUR	0.0%
2015 Q2	-20.1 Million EUR	0.0%
2015 FY	-12.4 Million EUR	59.55%
2014 FY	-30.66 Million EUR	-687.18%
2014 Q4	-30.66 Million EUR	0.0%
2014 Q2	-25.68 Million EUR	0.0%
2013 FY	-3.89 Million EUR	68.49%
2013 Q4	-3.89 Million EUR	0.0%
2013 Q2	-6.81 Million EUR	0.0%
2012 Q4	-12.36 Million EUR	0.0%
2012 Q3	-12.36 Million EUR	0.0%
2012 FY	-12.36 Million EUR	0.0%

Peer Net Debt Comparison of Nanobiotix S.A.

Name	Net Debt	Net Debt Difference
Boiron SA	-60.34 Million EUR	50.615%
Laboratorios Farmaceuticos Rovi, S.A.	21.31 Million EUR	239.821%
Vetoquinol SA	-129.83 Million EUR	77.048%
Valneva SE	82.73 Million EUR	136.018%
AB Science S.A.	13.03 Million EUR	328.615%
PHAXIAM Therapeutics S.A.	-275 Thousand EUR	-10736.364%
Vivoryon Therapeutics N.V.	-18.52 Million EUR	-60.872%
BioSenic S.A.	28.04 Million EUR	206.262%
ABIVAX Société Anonyme	-196.47 Million EUR	84.833%
Formycon AG	2.45 Million EUR	1315.83%